These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays. Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273 [TBL] [Abstract][Full Text] [Related]
4. The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders. Nencini F; Vultaggio A; Pratesi S; Cammelli D; Milla M; Fiori G; Bagnoli S; Prignano F; Romagnani S; Maggi E; Matucci A J Allergy Clin Immunol Pract; 2018; 6(6):2065-2072.e2. PubMed ID: 29660428 [TBL] [Abstract][Full Text] [Related]
5. Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays. Afonso J; Lopes S; Gonçalves R; Caldeira P; Lago P; Tavares de Sousa H; Ramos J; Gonçalves AR; Ministro P; Rosa I; Vieira AI; Coelho R; Tavares P; Soares J; Sousa AL; Carvalho D; Sousa P; da Silva JP; Meira T; Silva Ferreira F; Dias CC; Chowers Y; Ben-Horin S; Magro F; Therap Adv Gastroenterol; 2016 Nov; 9(6):781-794. PubMed ID: 27803733 [TBL] [Abstract][Full Text] [Related]
6. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317 [TBL] [Abstract][Full Text] [Related]
7. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment. Brandse JF; Vos LM; Jansen J; Schakel T; Ponsioen CI; van den Brink GR; D'Haens GR; Löwenberg M J Crohns Colitis; 2015 Nov; 9(11):973-81. PubMed ID: 26116557 [TBL] [Abstract][Full Text] [Related]
8. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab. Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874 [TBL] [Abstract][Full Text] [Related]
9. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients. Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273 [TBL] [Abstract][Full Text] [Related]
10. Use of anti-TNF drug levels to optimise patient management. Papamichael K; Cheifetz AS Frontline Gastroenterol; 2016 Oct; 7(4):289-300. PubMed ID: 28839870 [TBL] [Abstract][Full Text] [Related]
11. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis. Qiu Y; Mao R; Chen BL; Zhang SH; Guo J; He Y; Zeng ZR; Ben-Horin S; Chen MH Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1359-1372.e6. PubMed ID: 28232073 [TBL] [Abstract][Full Text] [Related]